Systematic NT-proBNP and ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm, Sweden - STROKESTOP II

简要总结

主要结局

次要结局

• Number of subjects with new discovered AF using intermittent ECG-recordings in the high risk Group with NT-proBNP>125 ng/L.(Two years)
• Incidence of major bleeding, ischaemic stroke, systemic embolism and death in the control group vs the intervention group(Five years)
• Cost per gained quality-adjusted life-year (QALY) and cost per avoided stroke of the STROKESTOP II screening program.(Five years)
• To assess screening uptake with regards to socio-demographic factors and to study if we can improve uptake in the screening programme by decentralizing the recruitment procedure.(Two years)
• Plasma and serum biomarkers and their relation to incidence of new AF and short episodes of AF (micro-AF)(Five years)
• To assess the incidence of heart failure in patients with NT-proBNP>125ng/L(Five years)
• To study the diagnostic performance of pulse-palpation in AF screening as compared to one-lead ECG(Four years)
• To study atrial function in patients with and without silent atrial fibrillation(Five years)
• To study the correlation between symptoms and newly discovered AF(Four years)
• To study the association of very short episodes of AF (micro-AF, episodes lasting shorter than 30 seconds) and incident AF(Two years)
• To compare different ECG modalities for AF screening(Two years)
• Incidence of undiagnosed hypertension in participants(four years)